Adiponectin receptor gene expression in human skeletal muscle cells is not regulated by fibrates and thiazolidinediones

International Journal of Obesity

Volumn 29, Issue 7, 2005, Pages 760-765

  Kaltenbach, S ^a   Staiger, H ^a   Weisser, M ^a   Haas, C ^a   Stumvoll, M ^b   Machicao, F ^a   Haring H U ^a,c  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b UNIVERSITY OF LEIPZIG   (Germany)

^c Medical Clinic Tubingen   (Germany)

Author keywords

Adiponectin receptor; Fibrate; PPAR ; PPAR ; Thiazolidinedione

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ADIPONECTIN; ADIPONECTIN RECEPTOR; ADIPONECTIN RECEPTOR 2; FENOFIBRATE; FIBRIC ACID DERIVATIVE; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PIRINIXIC ACID; RECEPTOR PROTEIN; ROSIGLITAZONE; TROGLITAZONE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; DRUG ACTIVITY; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IN VITRO STUDY; INSULIN RESISTANCE; INSULIN SENSITIVITY; MACROPHAGE; MALE; MUSCLE CELL; MYOTUBE; NORMAL HUMAN; PRIORITY JOURNAL; SKELETAL MUSCLE;

EID: 21244447992     PISSN: 03070565     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.ijo.0802957     Document Type: Article

References (26)

1. Chandran M, Phillips S, Ciaraldi T, Henry R. Adiponectin: more than just another fat cell hormone? Diabetes Care 2003; 26: 2442-2450.
2. Yamauchi T, Kamon J, Ito Y, Tsuchida A, Yokomizo T, Kita S, Sugiyama T, Miyagishi M, Hara K, Tsunoda M, Murakami K, Ohteki T, Uchida S, Takekawa S, Waki H, Tsuno NH, Shibata Y, Terauchi Y, Froguel P, Tobe K, Koyasu S, Taira K, Kitamura T, Shimizu T, Nagai R, Kadowaki T. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 2003; 423: 762-769.
3. Civitarese AE, Jenkinson CP, Richardson D, Bajaj M, Cusi K, Kashyap S, Berria R, Belfort R, DeFronzo RA, Mandarino LJ, Ravussin E. Adiponectin receptors gene expression and insulin sensitivity in non-diabetic Mexican Americans with or without a family history of type 2 diabetes. Diabetologia 2004; 47: 816-820.
4. Debard C, Laville M, Berbe V, Loizon E, Guillet C, Morio-Liondore B, Boirie Y, Vidal H. Expression of key genes of fatty acid oxidation, including adiponectin receptors, in skeletal muscle of type 2 diabetic patients. Diabetologia 2004; 47: 917-925.
5. Chinetti G, Zawadski C, Fruchart JC, Staels B. Expression of adiponectin receptors in human macrophages and regulation by agonists of the nuclear receptors PPARα, PPARγ and LXR. Biochem Biophys Res Commun 2004; 31: 151-158.
6. Adams M, Montague CT, Prins JB, Holder JC, Smith SA, Sanders L, Digby JE, Sewter CP, Lazar MA, Chatterjee VK, ÓRahilly S. Activators of peroxisome proliferator-activated receptor γ have depot-specific effects on human preadipocyte differentiation. J Clin Invest 1997; 100: 3149-3153.
7. Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, Kliewer SA. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPARγ). J Biol Chem 1995; 270: 12953-12956.
8. Spiegelman BM. PPARγ: adipogenic regulator and thiazolidinedione receptor. Diabetes 1998; 47: 507-514.
9. Stumvoll M. Thiazolidinediones-some recent developments. Expert Opin Investig Drugs 2003; 12: 1179-1187.
10. Fruchart JC, Duriez P, Staels B. Peroxisome proliferator-activated receptor-alpha activators regulate genes governing lipoprotein metabolism, vascular inflammation and atherosclerosis. Curr Opin Lipidol 1999; 10: 245-257.
11. Ye JM, Doyle PJ, Iglesias MA, Watson DG, Cooney GJ, Kraegen EW. Peroxisome proliferator-activated receptor (PPAR)-α activation lowers muscle lipids and improves insulin-sensitivity in high fat-fed rats: comparison with PPAR-γ activation. Diabetes 2001; 50: 411-417.
12. Moller DE, Berger JP. Role of PPARs in the regulation of obesity-related insulin sensitivity and inflammation. Int J Obes Relat Metab Disord 2003; 27: 17-21.
13. Krützfeld J, Kausch C, Volk A, Klein HH, Rett K, Häring HU, Stumvoll M. Insulin signaling and action in cultured skeletal muscle cells from lean healthy subjects with high and low insulin sensitivity. Diabetes 2000; 49: 992-998.
14. Wahl HG, Kausch C, Machicao F, Rett K, Stumvoll M, Häring HU. Troglitazone downregulates delta-6 desaturase gene expression in human skeletal muscle cell cultures. Diabetes 2002; 51: 1060-1065.
15. Park KS, Ciaraldi TP, Lindgren K, Abrams-Carter L, Mudaliar S, Nikoulina SE, Tufari SR, Veerkamp JH, Vidal-Puig A, Henry RR. Troglitazone effects on gene expression in human skeletal muscle of type II diabetes involve up-regulation of peroxisome proliferator-activated receptor γ. J Clin Endocrinol Metab 1998; 83: 2830-2835.
16. Kausch C, Kruetzfeld J, Witke A, Rettig A, Bachmann O, Rett K, Matthaei S, Machicao F, Häring HU, Stumvoll M. Effects of troglitazone on cellular differentiation, insulin signalling, and glucose metabolism in cultured human skeletal muscle cells. Biochem Biophys Res Commun 2000; 280: 664-674.
17. Muoio DM, Way JM, Tanner CJ, Winegar DA, Kliewer SA, Houmard JA, Kraus WE, Dohm GL. Peroxisome proliferator-activated receptor-α regulates fatty acid utilization in primary human skeletal muscle cells. Diabetes 2002; 51: 901-909.
18. Burant CF, Sreenan S, Hirano K, Tai TA, Lohmiller J, Lukens J, Davidson NO, Ross S, Graves RA. Troglitazone action is independent of adipose tissue. J Clin Invest 1997; 100: 2900-2908.
19. Park KS, Ciaraldi TP, Abrams-Carter L, Mudaliar S, Nikoulina SE, Henry RR. Troglitazone regulation of glucose metabolism in human skeletal muscle cultures from obese type II diabetic subjects. J Clin Endocrinol Metab 1998; 83: 1636-1643.
20. Maeda N, Takahashi M, Funahashi T, Kihara S, Nishizawa H, Kishida K, Nagaretani H, Matsuda M, Komuro R, Ouchi N, Kuriyama H, Hotta K, Nakamura T, Shimomura I, Matsuzawa Y. PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes 2001; 50: 2094-2099.
21. Katsuki A, Sumida Y, Murata K, Furuta M, Araki-Sasaki R, Tsuchihashi K, Hori Y, Yano Y, Gabazza EC, Adachi Y. Troglitazone reduces plasma levels of tumor necrosis factor-alpha in obese patients with type 2 diabetes. Diabetes Obes Metab 2000; 2: 189-1869.
22. Spiegelman BM, Flier JS. Adipogenesis and obesity: rounding out the big picture. Cell 1996; 87: 377-389.
23. Hofmann C, Lorenz K, Braithwaite SS, Colca JR, Palazuk BJ, Hotamisligil SG, Spiegelman BM. Altered gene expression for tumor necrosis factor-α and its receptor during drug and dietary modulation of insulin resistance. Endocrinology 1994; 134: 264-270.
24. Szalokowski D, White-Carrington S, Berger J, Zhang B. Antidiabetic thiazolidinediones block the inhibitory effect of tumor necrosis factor-α on differentiation, insulin-stimulated glucose uptake, and gene expression in 3T3-L1 cells. Endocrinology 1995; 136: 1474-1481.
25. Rieusset J, Auwerx J, Vidal H. Regulation of gene expression by activation of the peroxisome proliferator-activated receptor gamma with rosiglitazone (BRL 49653) in human adipocytes. Biochem Biophys Res Commun 1999; 265: 265-271.
26. De Vos P, Lefebvre AM, Miller SG, Guerre-Millo M, Wong K, Saladin R, Hamann LG, Staels B, Briggs MR, Auwerx J. Thiazolidinediones repress ob gene expression in rodents via activation of peroxisome proliferator-activated receptor gamma. J Clin Invest 1996; 98: 1004-1009.